Job ID 86459
Job Type Full-time
Exactmer is a start-up dedicated to producing precision polymeric molecules with our patented Nanostar Sieving Technology. Using this disruptive new platform, we are creating exquisite synthetic and biological polymers, including oligonucleotides and mono-disperse polyethylene glycols (PEGs), antibody-drug conjugate (ADC)-linkers, peptides and more…most of them bound for use in medicines that enhance patient quality of life.
We are a young, diverse team located in London and currently in a rapid phase of growth. We are searching for a self-starting, dynamic, flexible, and committed individual to join us. We are seeking an outstanding chemist to work on creating long-term value for the business through delivering high quality laboratory and kilo scale chemistry at the boundaries of research and production.
You will work on a wide range of chemistries, across synthesis, purification and analysis of biopolymers including oligonucleotides, and synthetic polymers including PEGs. You will deal with preparation of monomers for iterative synthetic processes; synthesis through repeated coupling and deprotection reactions, and membrane separation. Analysis using LC-MS, SEC/GPC, NMR and other techniques is a significant part of your responsibilities. Excellent record-keeping and adherence to safety codes and protocols are essential. Overall, you need to be flexible and ready to grow your skills and experience as the company grows and our technology evolves.
Candidates should have a chemistry PhD, with a desire to learn fast and tackle many different aspects of creating a new technology and new products. Experience would be a bonus and we are open to candidates at different career stages. We offer an attractive renumeration package.
To find out more, contact Andrew Livingston on email@example.com. To apply, send Andrew your 2-page CV and a letter covering your background and interest in this role. We will be continuously reviewing applicants but prefer applications before Friday December 9thth 2022.